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Immunoproteasomes Largely Replace Constitutive Proteasomes
During an Antiviral and Antibacterial Immune Response in
the Liver1
Selina Khan,2* Maries van den Broek,2‡ Katrin Schwarz,2* Rita de Giuli,*
Pierre-Andre´ Diener,† and Marcus Groettrup3*
The proteasome is critically involved in the production of MHC class I-restricted T cell epitopes. Proteasome activity and epitope
production are altered by IFN- treatment, which leads to a gradual replacement of constitutive proteasomes by immunopro-
teasomes in vitro. However, a quantitative analysis of changes in the steady state subunit composition of proteasomes during an
immune response against viruses or bacteria in vivo has not been reported. Here we show that the infection of mice with
lymphocytic choriomeningitis virus or Listeria monocytogenes leads to an almost complete replacement of constitutive proteasomes
by immunoproteasomes in the liver within 7 days. Proteasome replacements were markedly reduced in IFN-/ mice, but were
only slightly affected in IFN-R/ and perforin/ mice. The proteasome regulator PA28/ was up-regulated, whereas PA28
was reduced in the liver of lymphocytic choriomeningitis virus-infected mice. Proteasome replacements in the liver strongly altered
proteasome activity and were unexpected to this extent, since an in vivo half-life of 12 days had been previously assigned to
constitutive proteasomes in the liver. Our results suggest that during the peak phase of viral and bacterial elimination the antiviral
cytotoxic T lymphocyte response is directed mainly to immunoproteasome-dependent T cell epitopes, which would be a novel
parameter for the design of vaccines. The Journal of Immunology, 2001, 167: 6859–6868.
T he proteasome is a proteolytic system that selectively ter-minates the function of proteins in the cell by degradingthem to peptides (1). The immune system makes use of
these peptides as ligands for MHC class I molecules to be pre-
sented to CTL. As part of the MHC class I pathway the immune
system has developed the ability to modify proteasome activity in
inflammatory sites through the cytokine-mediated induction and
replacement of proteasome active site subunits and regulators (2).
Although this phenomenon has been studied extensively in vitro,
little is known about the extent to which proteasome subunit re-
placements occur during an ongoing immune response in an in-
flamed tissue in vivo. Hence, we decided to examine the subunit
composition of proteasomes in the liver of lymphocytic chorio-
meningitis virus (LCMV)-4 and Listeria monocytogenes
(Lm)-infected mice.
The proteasome system consists of a proteolytic core unit, the
20S proteasome, and regulators such as PA700, PA28/, PA28,
and PI31, which control substrate acquisition and catalytic activity
of the proteasome. The 20S proteasome is constructed like a barrel
of four stacked rings. The two outer rings contain seven different
subunits of the  type, whereas the inner two rings contain seven
different subunits of the  type that are numbered according to
their positions in the ring. The subunits 1 (,Y), 2 (MC14,
LMP9, Z), and 5 (MB1, X) bear the catalytically active sites of
the 20S proteasome facing the inner cavity of the protease. When
cells are treated with the inflammatory cytokines IFN- and
TNF-, three additional active site subunits, named 1i (LMP2),
2i (MECL-1), and 5i (LMP7), are transcriptionally induced and
take the place of their constitutive homologues during proteasome
neosynthesis. This substitution of active site subunits changes the
proteolytic specificity of the proteasome (3–6) and leads to marked
changes in the distribution of fragments that are produced from
polypeptides (7, 8). The exchange of LMP2 for  was unanimously
reported to down-regulate cleavages C-terminal of acidic residues
(the caspase-like activity) and favor the cleavage C-terminal of
hydrophobic residues (the chymotrypsin-like activity). This
change in cleavage specificity conforms to structural requirements
of class I peptide ligands that possess hydrophobic C termini in the
mouse and either hydrophobic or basic C termini in the human.
Conflicting data have been reported on the effects of the two other
subunit exchanges of LMP7 for MB1 (8–10) and MECL-1 for
MC14 (Z) (11), and structural analysis does not predict major
changes in the specificity of the P1 pockets (12), leaving the func-
tions of these latter two exchanges elusive. With respect to the bulk
production of MHC class I ligands, it was found in LMP2- and
LMP7-deficient cell lines (13, 14) that these subunits are not gen-
erally required to maintain class I cell surface expression. For the
generation of specific epitopes, however, the expression of either
LMP2 or LMP7 can be pivotal. Several epitopes were produced
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inefficiently or not at all in the absence of LMP2 (15, 16) or LMP7
(17–22), but the opposite case has recently been reported for sev-
eral epitopes from tumor Ags that were destroyed when LMP2 and
LMP7 were expressed at high levels (23). Consistent with these in
vitro results, it was recently found in LMP2/ mice that this
subunit has a pivotal influence on the hierarchy of T cell epitopes
from influenza virus (24).
A further component of the proteasome system that has a pro-
nounced effect on Ag processing is the proteasome regulator
PA28/. Both, the  and  subunits of this ring-shaped regulator
are inducible with IFN- at both mRNA and protein levels (25).
PA28/ stimulates the various proteolytic activities of the pro-
teasome to different extents and markedly alters the fragmentation
of polypeptides through the 20S proteasome (8, 26, 27). Overex-
pression of PA28/ in cell lines resulted in a higher presentation
of some (28–30), but not all, T cell epitopes (22), suggesting a role
for PA28/ in Ag processing that was recently confirmed in
PA28/ mice (31). A homologue of PA28/ that is not tran-
scriptionally induced by IFN- is named Ki Ag or PA28. The
single subunit of PA28 forms heptahomomeric rings that associ-
ate with the proteasome and are predominantly found in the nu-
cleus. Interestingly, the PA28 protein appears to be down-regu-
lated upon the IFN- treatment of cell lines in vitro and in
transgenic mice that constitutively express IFN- in the liver (32).
PA28/ mice were slightly retarded in growth (33), but the
function of PA28 that causes this phenotype has remained
elusive.
Taken together it appears that the inducible proteasome subunits
LMP2, LMP7, and MECL-1 as well as the proteasome regulator
PA28/ are not needed to guarantee the bulk flow of MHC class
I ligands, but for the generation of unique epitopes they often have
a decisive impact. Based on these insights, two hypotheses can be
envisaged as to why the immunoproteasomes and PA28/ co-
evolved with the MHC class I pathway. It may be that these factors
are induced to generate different sets of proteasome complexes in
a cell to enlarge the diversity of peptide processing, which would
allow the processing of a given antigenic protein in several ways.
For this scenario it should be useful to express approximately
equal amounts of constitutive proteasomes and immunoprotea-
somes in an inflamed tissue. Alternatively, it could be that CTLs
are meant to be directed to a different set of peptides in an inflam-
matory site compared with noninflamed tissues, and this could
only be achieved if constitutive proteasomes were largely replaced
by immunoproteasomes. We have investigated in this study the
steady state composition of 20S proteasomes of the liver on several
days during the course of an infection of the mouse with the hepa-
totropic WE strain of LCMV and the bacterium Lm. Unexpect-
edly, the infections led to virtually complete replacement of con-
stitutive proteasomes by immunoproteasomes and strong induction
of PA28/ as well as the disappearance of PA28 on days 7 and
8 of the infection, when the cytotoxic immune response is maximal
and pathogen numbers decline. Our results suggest that the cyto-
toxic immune response in the infected liver will be predominantly
directed to a set of T cell epitopes that are produced by immuno-
proteasomes, while the T cell response is clearing the virus. This
finding argues against the maximal diversity argument and sug-
gests that it must be beneficial for the immune response to convert
epitope production to a set of peptides that is produced by immu-
noproteasomes and PA28/.
Materials and Methods
Mice and cell lines
C57BL/6 mice (H-2b) and BALB/c mice (H-2d) were purchased from In-
stitut fu¨r Labortierkunde, Tierspital Zurich (Zurich, Switzerland), and kept
in a specific pathogen-free environment. Mice deficient for IFN- (34),
IFN-R (35), and perforin (36) have been described previously. MC57 is
a C57BL/6-derived methylcholantrene-induced fibrosarcoma cell line (37),
and B8 is a BALB/c-derived SV40-induced fibroblast line (38). H2.35 is a
mouse hepatocyte cell line that we obtained from American Type Culture
Collection (Manassas, VA). All cell lines were grown in IMDM or RPMI
1640 medium supplemented 10% FCS, 2 mM L-glutamine, and 100 U/ml
penicillin/streptomycin.
Flow cytometry
For surface staining, aliquots of 5  105 cells in PBS and 2% FCS were
incubated for 15 min in a round-bottom 96-well plate on ice with the mouse
mAb KL25 specific for the LCMV glycoprotein (39). The cells were
washed three times and subsequently stained by FITC-conjugated goat anti-
mouse Ig secondary Ab (Silenus, Melbourne, Australia). After two wash-
ing steps the cells were analyzed on a FACScan flow cytometer (BD Bio-
sciences, Mountain View, CA).
LCMV, Listeria, and infection of mice
LCMV-WE was propagated in the L929 fibroblast line, and viral stocks
were kept at 70°C (40). The virus was grown and titrated on L929 cells
exactly as previously described (41). Mice were infected i.v. with 200 PFU
(low dose) or 106 PFU (high dose) LCMV-WE. After the indicated days
the mice were sacrificed, and the livers were excised for purification of 20S
proteasomes and for Western analysis. Spleen and liver samples were used
for determination of LCMV titers, and peripheral blood was used for IFN-
ELISA. Serum levels of IFN- were below detection levels on all days of
infection except day 4, when 10–30 U/ml was found.
For Listeria infection, mice were infected i.v. with 9800 CFU Lm
10304S in PBS. Lm were cultured overnight at 37°C in brain-heart infusion
broth. On the day of infection, 10-fold serial dilutions of the inoculum were
plated on brain-heart infusion agar plates and incubated overnight at 37°C.
The exact amount of bacteria injected the day before was calculated from
these plates.
Purification of 20S proteasomes from mouse liver and
fluorogenic assays
20S proteasomes from two or three mouse livers were purified and quan-
titated as detailed previously (42). Hydrolytic assays for proteasome ac-
tivity employing fluorogenic assays were performed as previously de-
scribed (43). PA28/ complexes were not detected in the proteasome
preparations according to Western analysis (data not shown).
Two-dimensional gel electrophoresis
For Figs. 2–5 aliquots of 60 g purified 20S proteasomes were separated
on two-dimensional nonequilibrium pH gradient gel electrophoresis
(NEPHGE)/SDS-PAGE or isoelectric focusing/SDS-PAGE exactly as pre-
viously described (44). After the run, the gels were stained with Coomassie
brilliant blue R250. For quantitation, the gels were scanned and analyzed
using AIDA software (Fuji, Tokyo, Japan).
Metabolic labeling and immunoprecipitation
H2.35, B8, or MC57 cells were left untreated or were infected with
LCMV-WE at a multiplicity of infection of 0.01. One day after infection
cells were incubated with 100 U/ml mouse rIFN- for 16 h or were left
unstimulated. LCMV infection was confirmed flow cytometrically by
LCMV glycoprotein expression on the cell surface, and IFN- stimulation
was confirmed by up-regulation of H-2 class I expression. Cells were
starved in methionine/cysteine-free RPMI 1640 and 10% dialyzed FCS
with or without rIFN- for 30 min, labeled for 6 h with 0.2 mCi/ml Trans
35S label (ICN, Eschwege, Germany), and chased for 18 h with or without
rIFN-. The cells were harvested by trypsinization and lysed by sonication
in buffer A (25 mM Tris (pH 7.6), 2 mM MgCl2, 17% glycerol, 1 mM DTT,
and 2 mM ATP). The postnuclear lysates were counted for 35S incorpo-
ration, and equal aliquots were used for immunoprecipitation. The lysate
was precleared for 1 h with protein G-Sepharose CL-4B (Pharmacia, Upp-
sala, Sweden), followed by immunoprecipitation with an anti-proteasome
serum (30) bound to protein G-Sepharose for 4 h at 4°C. The precipitates
were washed with buffer A, separated by NEPHGE/SDS-PAGE, and vi-
sualized on x-ray films by autoradiography.
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Western blot analysis and sucrose gradient density
centrifugation
In Fig. 6 liver specimens were lysed in buffer B (50 mM Tris-HCl (pH 7.5),
5 mM MgCl2, 1 mM EDTA, 1% SDS, 0.75 M aprotinin, 10 M leupep-
tin, 2.8 M pepstatin, and 0.85 mM PMSF) in a Dounce homogenizer
(Kontes, Vineland, NJ), and 100 g total protein/lane was separated by
SDS-PAGE. In Fig. 2D liver samples from C57BL6 mice on day 8 of
LCMV infection were lysed in buffer C (25 mM Tris-HCl (pH 7.5) and 2
mM MgCl2) in a Dounce homogenizer with subsequent sonication. Post-
nuclear supernatants were loaded onto a 10–40% sucrose gradient and
centrifuged at 40,000 rpm in a Beckman SW40Ti rotor (Palo Alto, CA) for
16 h. Gradient fractions of 0.6 ml were drawn, proteasome activity was
determined to confirm proper separation, and proteins were separated on
SDS-PAGE. The proteins were blotted onto nitrocellulose membrane
(Schleicher & Schuell, Dassel, Germany), blocked with PBS/5% (w/v) low
fat dry milk/0.1% Tween 20 for 1 h, and agitated overnight at 4°C with the
described rabbit antisera specific for peptides PA28 and PA28 (45).
Rabbit antisera for mouse LMP7 and PA28 were raised against the key-
hole limpet hemocyanin-coupled peptides SDVSDLLYKYGEAAL and
ILLTNSHDGLDGPTYK, respectively. The MC3 Ab has been described
previously (46). The blots were washed and incubated for 1 h with HRP-
conjugated secondary Ab. After extensive washing with PBS/0.1% Tween 20,
proteins were visualized on x-ray films by enhanced chemiluminescence.
Real-time RT-PCR
Total RNA was extracted from mouse liver tissue using TRIzol reagent
(Life Technologies, Basel, Switzerland). cDNA was synthesized from 3 g
RNA using 2 mM dT15, 2 mM dNTPs, 0.6 U/l RNasin (Promega, Wal-
lisellen, Switzerland), 200 U Moloney murine leukemia virus RT (Pro-
mega)/reaction (1 h at 42°C). After cDNA synthesis, the nucleic acids were
precipitated in 0.3 M NaCl/80% ethanol, and the pellet was washed twice
in 70% ethanol. The samples were resuspended in H2O. Real-time PCR
was performed with a Light Cycler (Roche, Basel) using the DNA Master
SYBR Green I reaction mix (Roche) and 0.5 pmol/l of each primer in 3.5
mM MgCl2. Sense and antisense primers used for PCR amplification were
(annealing temperatures (a.t.) given in parentheses): mouse (mo) LMP2,
5-TCCACACCGGGACAACC-3 and 5-CCAGCCAGCTACTATGAG
ATGC-3 (a.t.  62°C); moDELTA, 5-TCGAGTGACTGACAAGCT
GACC-3 and 5-GAACAGAGTACACCTGCCCTCC-3 (a.t.  62°C);
moLMP7, 5-CTCCGTGTCTGCAGCATCC-3 and 5-TCCACTTTCAC
CCAACCGTC-3 (a.t.  58°C); moMB1, 5-CTTGACGGAACCACCACC-3
and 5-CCATAGACAGCCCCATGC-3 (a.t.  58°C); moTNF-, 5-GCACA
GAAAGCATGATCC-3 and 5-TGTCCCTTGAAGAGAACC-3 (a.t. 
62°C); and mouse hypoxanthine phosphoribosyltransferase (HPRT): 5-
GCTGGTGAAAAGGACCTC-3 and 5-CACAGGACTAGAACACCTGC-3
(a.t. 60°C). The runs were programmed as follows: denaturation for 30 s
at 95°C; amplification (40 cycles, with readings of the fluorescence at the
end of each cycle) for 1 s at 95°C, 10 s at a.t., and 20 s at 72°C; and analysis
of the products (reading of the fluorescence in a continuous mode) for 0 s
at 95°C, 62 to 95°C transition with 0.1°C increment/sec. For mouse IFN-
we used a conventional PCR mix containing the PCR primers moIFN
(5-GACAATGAACGCTACACACTGC-3 and 5-GGACAATCTCTTC
CCCACC-3; a.t.  58°C) and the fluorescence resonance energy transfer
primers (5-TGCCAAGTTTGAGGTCAACAACCCACA-fluorescein-3
and 5-LCred640-GTCCAGCGCCAAGCATTCAATGAGC-3); reading
of fluorescence was performed after annealing. Analysis was performed
with Light Cycler software 3. The value calculated by the quantification
analysis was always within the range covered by three concentrations of
sample that were taken as arbitrary units to construct the standard curve for
linear regression with r  1.0 and p  0.0001. The cDNAs were normal-
ized to HPRT mRNA content. The specificity of the amplification was
checked with melting curve analysis of the products as well as analysis on
an agarose gel.
Results
LCMV-WE does not induce immunoproteasomes by itself and
does not interfere with the IFN--mediated induction of
immunoproteasomes
To investigate how the steady state composition of 20S protea-
some subunits changes during the course of a viral infection it was
important to choose a virus that infects an entire organ in a well-
documented manner and reproducible time course. The infection
of the mouse with the hepatotropic strain WE of LCMV is a suit-
able model system to address this question, because this virus
readily replicates in hepatocytes, Kupffer cells, fibroblasts, endo-
thelial cells, and other cell types of the liver, and it rapidly spreads
throughout the organ (47–49). Moreover, LCMV-WE elicits a
strong and well-characterized CTL response that is maximal on
day 8 of infection and leads to elimination of the virus. However,
as some viruses interfere with the induction of immunoprotea-
somes (50, 51), we decided to initially test whether this was also
the case for LCMV-WE. The mouse hepatocyte line H2.35 as well
as B8 or MC57 fibroblasts were infected with LCMV-WE and
after 1 day were cultivated in the presence or the absence of IFN-
for 16 h before metabolic labeling. Proteasomes were immunopre-
cipitated, and the subunit composition was analyzed by two-di-
mensional NEPHGE/SDS-PAGE (Fig. 1A). Inductions of LMP2
or LMP7 were not observed in H2.35 cells (Fig. 1) or in B8 or
MC57 cells (data not shown) upon LCMV-WE infection, although
the cells were productively infected, as documented by flow cy-
tometric analysis of LCMV glycoprotein expression on the cell
surface (data not shown). Moreover, an interference of LCMV-WE
with the IFN- mediated induction of LMP2 and LMP7 was not
observed, which was a prerequisite for monitoring their in vivo
induction in infected mice.
Gradual and extensive replacement of constitutive proteasomes
by immunoproteasomes in the liver of LCMV-infected mice
Mice of the C57BL/6 strain were infected i.v. with a high dose
(106 PFU) of LCMV-WE, and two livers each from uninfected
mice and mice on days 2, 4, 8, 12, and 25 after infection were used
to purify 20S proteasomes. The subunits of the 20S proteasomes
were separated by two-dimensional NEPHGE/SDS-PAGE, and the
proteins were visualized by Coomassie staining. This method al-
lows a reliable quantification of the steady state amounts of pro-
teasome subunits and the relative intensity changes during subunit
replacements. The results shown in Fig. 2A reveal that uninfected
mice express very little LMP2 and LMP7 in the liver compared
with the constitutive subunits  and MB1. The protein spots for
these four subunits as well as the constitutive and invariant -type
subunit C6 were quantified by densitometry, and the data are
shown in Fig. 2B. On day 2 postinfection the inducible subunits
had already begun to rise, and by day 4 LMP2 and  were equally
FIGURE 1. Effect of LCMV-WE infection on the induction of LMP2
and LMP7. A, NEPHGE/SDS-PAGE of proteasome immunoprecipitates
from metabolically labeled H2.35 hepatocytes. Cells were treated for 2
days with rIFN- and/or infected with LCMV-WE as indicated below each
autoradiography. The positions of the proteasome subunits LMP2 (1i),
LMP7 (5i),  (1), and MB1 (5) are marked by arrows; the molecular
mass is given in kilodaltons at the right. The spot marked with an asterisk
in the top left panel is unspecific.
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prominent, whereas the LMP7 spots were already twice as inten-
sive as that for MB1. On day 8 of infection, when virus titers start
to decline (Table I) and the cytotoxic immune response and the
expansion of LCMV-specific CD8 T cells are usually maximal
(47, 52), we observed an almost complete replacement of  by
LMP2 and of MB1 by LMP7. The 8-fold reduction of MB1 and the
4-fold reduction of  by day 8 of infection were unexpected, as the
constitutive proteasome was reported to possess an in vivo half-life
of 12–15 days in rat livers (53). The exchange of MC14 by
MECL-1 on day 8 was analyzed on isoelectric focusing-SDS-
PAGE two-dimensional gels, because it was not readily resolved
by NEPHGE/SDS-PAGE and was found to occur to an extent of
only 50% (data not shown) as has been previously documented for
IFN--treated cells (44). On day 12 postinfection, when virus titers
were 100-fold reduced, the ratio of inducible to constitutive sub-
units started to revert again, but even on day 25 of infection the
FIGURE 2. Composition of 20S proteasome sub-
units purified from livers of LCMV-WE-infected
C57BL/6 mice. A, NEPHGE/SDS-PAGE analysis of
60 g 20S proteasome purified from the liver of un-
infected mice or mice that had been infected with a
high dose of LCMV-WE (106 PFU) on the indicated
days before organ removal. The proteins were visual-
ized by Coomassie stain. The positions of proteasome
subunits LMP2, LMP7, , MB1, and C6 are indicated;
the two spots assigned to LMP7 were confirmed by
Western blotting (not shown). B, Densitometric eval-
uation of indicated proteasome subunits from the two-
dimensional gels shown in A. C, Western analysis of
the proteasome subunits MB1, LMP7, , and LMP2 in
livers of LCMV-WE-infected C57BL/6 mice. The day
of infection is indicated at the top, and the results of
densitometric analysis of bands on x-ray films are
shown below each lane in arbitrary units (a.u.). D,
LMP7 and MC3 Western analysis of sucrose gradient
fractions prepared from livers of C57BL/6 mice on day
8 after LCMV infection. Proteasome activity was de-
tected in fractions 12–14. Note the presence of mono-
meric LMP7 precursors (pLMP7) at the top of the
gradient.
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constitutive proteasome subunits  and MB1 had not yet reached
preinfection levels.
To investigate how mRNA levels of inducible and constitutive
subunits were changed during the infection, we analyzed two
C57BL/6 mice on days 0, 4, 8, and 11 of infection by real-time
RT-PCR using the mRNA level of HPRT as a standard. As shown
in Table II, the mRNAs for LMP2 and LMP7 were elevated by
factors of 3.95 and 2.55 on day 8 of infection, respectively, and
declined thereafter, which correlated with the incorporation of the
respective proteins into proteasomes. Much less expected was the
well-reproducible decline in the mRNAs for the constitutive sub-
units  and MB1, which we have not observed in previous studies
when cells were treated with IFN- in vitro (54). The factors re-
sponsible for this mRNA down-regulation of  and MB1 in vivo
remain to be identified. To examine whether IFN- and TNF-,
which have been shown to enhance LMP2 and LMP7 in vitro, are
actually elevated during the infection we quantified their mRNA
from the same cDNA samples. The elevations of IFN- and
TNF- mRNAs on day 4 of infection were only 1.61- and 3.2-fold,
respectively, thus raising some doubt as to whether such a weak
up-regulation can be sufficient to transcriptionally induce LMP2
and LMP7 or whether other cytokines are involved at that stage.
On day 8 of infection, however, the 5.5-fold elevation of IFN-
and the 43.0-fold elevation of TNF- are consistent with these
cytokines being responsible for immunosubunit induction at the
peak of the CTL response. The results were also congruent with
our histological examination, which revealed a massive infiltration
of lymphocytes on day 8, but not yet on day 4, of LCMV infection
(data not shown) in accordance with previous studies (47). West-
ern analysis was performed to determine the expression levels of
LMP2/ and LMP7/MB1 in lysates of liver samples throughout the
course of LCMV infection and fully confirmed the results obtained
with two-dimensional gels (Fig. 2C). The synthesis of LMP7 pre-
cursors on day 8 of infection was apparently so strong that not all
30-kDa precursors could be incorporated into assembling protea-
somes, as they were found on the top of sucrose gradients in con-
trast to the -type subunit MC3 (Fig. 2D).
To investigate whether the in vivo replacement of proteasomes
can also be observed in mice of a different MHC haplotype and
genetic background, we infected BALB/c mice with a high dose of
LCMV-WE and likewise isolated and analyzed 20S proteasomes
of the liver. Also in the BALB/c strain we repeatedly observed a
virtually complete exchange of constitutive proteasomes by im-
munoproteasomes already on day 7 postinfection (Fig. 3A). This
phenomenon was not dependent on infections with high doses of
LCMV-WE, as the subunit replacements were similar in the liver
of BALB/c mice that had been infected for 7 days with a low dose
of LCMV-WE (200 PFU), which is normally used as a physiolog-
ical equivalent in this experimental system. The quantitative anal-
ysis of the two-dimensional gels from the high dose and low dose
infections (Fig. 3B) confirmed that the virus dose did not alter the
rate of proteasome subunit replacements, and the same result was
obtained when C57BL/6 mice were infected with 200 PFU
LCMV-WE (data not shown).
In vivo replacement of  and MB1 by LMP2 and LMP7 is
largely dependent on IFN-, but only to a minor extent on
IFN- and perforin
Since IFN- is the cytokine that transcriptionally induces LMP2,
LMP7, and MECL-1 most vigorously (55), we decided to deter-
mine the extent of subunit replacement in the liver of IFN--de-
ficient BALB/c mice (34) that had been infected with a high or a
low dose of LCMV-WE 7 days previously (Fig. 4). In the absence
of IFN- the induction of LMP2 and LMP7 was reduced by about
50% despite an enhanced virus titer, indicating that a complete
replacement of active site proteasome subunits, as in the wild-type
BALB/c mouse, could not be obtained. Hence, other cytokines
must be able to induce the 7-fold induction of LMP2 and LMP7
observed in IFN-/ mice. We tested the effects of IFN- and -
in IFN-R/ mice and found that the replacement of constitutive
proteasomes by immunoproteasomes in the liver was only slightly
reduced. Apparently, type I IFNs do not contribute much to the
proteasome replacement in vivo, which is consistent with a lack of
LMP2 and LMP7 up-regulation after LCMV infection in vitro that
led to an induction of IFN-/ (data not shown). Another gene-
targeted mouse that we examined was the perforin/ mouse, be-
cause we wanted to determine whether perforin-mediated destruc-
tion of LCMV-infected cells in the liver by CTLs or NK cells
would be required to promote the removal of constitutive protea-
somes and the replacement by immunoproteasomes during tissue
regeneration. As shown in the bottom panel of Fig. 4, perforin
Table I. LCMV titers in liver samples from mice at indicated days after
infection with high (106 PFU) or low (200 PFU) doses of LCMV-WEa
Mouse Strain
Dose of
Infection
Day of
Infection LCMV Titer
C57BL/6 High 1 5.4  105; 4.5  105
C57BL/6 High 2 3.9  105; 6.3  105
C57BL/6 High 3 6.3  105; 7.8  105
C57BL/6 High 4 3.3  106; 4.5  106
C57BL/6 High 8 5.1  106; 3.9  106
C57BL/6 High 12 8.0  104; 1.0  105
C57BL/6 High 15 7.5  104; 9.0  104
C57BL/6 High 25 ND; ND
BALB/c Low 7 1.0  104; 1.0  104
BALB/c High 7 5.1  106; 7.8  106
BALB/c-IFN-/ High 7 7.2  106; 9.3  106
a Titers are given in PFU LCMV-WE per liver; ND, LCMV titers were below the
detection limit of the plaque assay.
Table II. Real time RT-PCR analysis of mRNA levels in the liver of C57BL/6 mice on different days of infection with 106 PFU of LCMV-WEa
Day LMP2 LMP7  MB1 IFN- TNF-
0 1.0 1.0 1.0 1.0 1.0 1.0
4 2.61  0.77 1.63  0.08 0.81  0.12 0.84  0.12 1.61  0.19 3.20  1.27
8 3.95  1.48 2.55  0.35 0.62  0.13 0.71  0.12 5.50  0.55 43.0  15.4
11 2.79  1.54 1.35  0.21 0.40  0.16 1.10  0.14 2.55  1.06 18.2  2.05
a Values represent factors of mRNA expression relative to the expression on day 0. Data are the means  SD from values of two mice. The mRNA expression for HPRT
was used to standardize the amount of cDNA, and results were very similar when -actin was used as a standard (data not shown).
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deficiency affected the replacement of constitutive proteasomes in
the liver to only a minor extent, suggesting that perforin-mediated
cell death contributed only marginally to these replacements.
Infection of mice with Listeria leads to an extensive replacement
of constitutive proteasomes by immunoproteasomes in the liver
We investigated whether the proteasome replacements in the liver
during LCMV infection was a virus-specific phenomenon or
whether an immune response against bacteria would have a similar
consequence. BALB/c mice were infected i.v. with 9800 CFU of
the Lm strain 10304S, and livers were removed on days 3 and 7
postinfection for isolation of 20S proteasomes and analysis on
Coomassie-stained two-dimensional gels. As depicted in Fig. 5,
Lm infection led to a comparable exchange of constitutive protea-
somes by immunoproteasomes as had previously been observed
with LCMV infection. The onset of proteasome replacements ap-
peared to be very early after Lm infection, as it was more pronounced
on day 3 of Lm infection than on day 4 after LCMV infection, a
finding that was consistently obtained in both BALB/c (Fig. 5) and
C57BL6 (data not shown) mice. Taken together, the extensive pro-
teasome exchanges observed during the course of LCMV infection do
not seem to be a solitary phenomenon confined to this virus, but may
be extended to bacteria and possibly other pathogens.
PA28 and  are up-regulated, whereas PA28 is down-
regulated, in the liver of LCMV-infected mice
Since PA28/ is known to be transcriptionally up-regulated by
IFN- and since PA28 was reported to be down-regulated by
IFN- by a to date uncharacterized post-transcriptional mecha-
nism, we decided to follow the protein levels of PA28-, -, and
- by Western analysis using peptide antisera against these three
subunits of proteasome regulators. Liver tissues were obtained
from C57BL/6 mice that were either uninfected or infected with a
high dose of LCMV-WE on the indicated days before analysis
(Fig. 6). The Western blots revealed that the amounts of PA28
and - increased by a factor of 3.5 from day 0 to day 8 of infection
and declined thereafter. As we have observed for the induction of
LMP2 and LMP7, the induction was already visible on day 3 after
LCMV infection and reached a peak when the CTL response is
expected to be maximal on day 8. Interestingly, the level of PA28
protein was strongly reduced during days 4, 8, and 15 of infection
compared with that in uninfected mice, which has not previously
been documented for a viral infection. In contrast to the induction
FIGURE 3. Composition of 20S proteasome
subunits from livers of BALB/c mice after low
dose and high dose infections with LCMV-WE.
A, NEPHGE/SDS-PAGE analysis of 60 g 20S
proteasome purified from the liver of uninfected
BALB/c mice or mice on day 7 after infection
with high (106 PFU) or low (200 PFU) doses of
LCMV-WE as indicated. The proteins were vi-
sualized by Coomassie stain, the positions of
proteasome subunits LMP2, LMP7, , and
MB1 are marked. B, Densitometric evaluation
of two-dimensional gels containing proteasome
subunits from uninfected and infected BALB/c
mice (A) and LCMV-infected IFN-/ mice
(Fig. 4).
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of LMP2 and LMP7 that occurred at least to some degree in IFN-
/ mice, neither the induction of PA28/ nor the disappear-
ance of PA28 occurred on day 7 after LCMV infection in the
absence of IFN-, indicating that other cytokines cannot compen-
sate for the lack of IFN- in this respect.
The peptidolytic activity of liver 20S proteasomes is strongly
altered during the infection with LCMV
To address what consequences the proteasome subunit replace-
ments during LCMV infection have on proteasome activity, we
determined the activity of purified 20S proteasomes from livers of
uninfected BALB/c mice as well as livers of LCMV-infected
BALB/c wild type and IFN-/ mice 7 days postinfection in
peptidolytic assays. The respective 20S proteasomes, which were
the same as those analyzed on the two-dimensional gels in Figs. 3
and 4, were incubated with the fluorogenic peptide substrates (Z)-
LLE--nitroanilide (NA), Suc-LLVY-7-amido-4-methylcouma-
rin (MCA), (Z)-GGL-MCA, and Bz-VGR-MCA, and the release
of the fluorogenic leaving groups NA or MCA was measured at
different substrate concentrations after 30, 60, and 90 min. The
60-min values of the linear and very reproducible reaction are
shown in Fig. 7 and indicate that the cleavage of the (Z)-LLE-NA
substrate at the C terminus of glutamic acid, which is frequently
used to determine the peptidylglutamyl peptide-hydrolyzing or
FIGURE 5. Effect of Lm infection on proteasome subunit composition
in the mouse liver. BALB/c mice were infected with 9800 CFU Lm
10304S, and 20S proteasomes were purified from livers on days 3 and 7
after infection. Proteasome subunits were separated on NEPHGE/SDS-
PAGE and stained with Coomassie blue.
FIGURE 6. Western analysis of PA28-, -, and - expression in the
livers of LCMV-infected mice. Liver samples were taken from C57BL/6
wild-type mice that were either uninfected (day 0) or had been infected
with 106 PFU LCMV-WE on the indicated days before hepatectomy. For
comparison, an IFN-/ BALB/c mouse was analyzed on day 7 post-
LCMV infection. Total lysates of liver samples were blotted and probed
with antisera specific for PA28, PA28, and PA28 as indicated, and
reactive bands were visualized on x-ray films by ECL. The position of a
30-kDa marker is indicated on the left.
FIGURE 7. Peptide hydrolyzing activity of 20S proteasomes purified
from the livers of LCMV-infected and uninfected (not inf.) BALB/c mice.
The purified 20S proteasomes from livers of uninfected BALB/c mice or
LCMV-WE-infected BALB/c wild-type and IFN-/ mice (the same
preparations as analyzed in Figs. 3 and 4) were assayed for hydrolysis of
the indicated fluorogenic substrates at various concentrations. The activi-
ties are calculated from fluorescence of the MCA or NA leaving groups
after 60 min of incubation. Values are the means of triplicate determina-
tions with an SE of 5% for all data points. d, Day.
FIGURE 4. Liver proteasomes from LCMV-infected mice deficient for
IFN-, IFN-R, and perforin were analyzed. 20S proteasomes were puri-
fied from the livers of IFN-/ (top), IFN-R/ (middle), and per-
forin/ (bottom) mice 7 days after infection with 106 PFU LCMV-WE.
Proteasome subunits were separated on NEPHGE/SDS-PAGE and stained
with Coomassie blue. The positions of proteasome subunits LMP2, LMP7,
, and MB1 are indicated.
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caspase-like activity of the proteasome, was almost completely lost
on day 7 of LCMV infection in wild-type mice and was reduced by
approximately 50% in IFN-/ mice. According to our previous
transfection experiments (8, 10), this dramatic change in the
caspase-like activity must be due to the replacement of  by LMP2,
which is almost quantitative in liver proteasomes on day 7 post-
LCMV infection. The trypsin-like activity, as determined by hy-
drolysis of the Bz-VGR-MCA substrate, was slightly reduced in
LCMV-infected mice, whereas the chymotrypsin-like activity
measured by hydrolysis of (Z)-GGL-MCA was not significantly
different among the three proteasome populations. The hydrolysis
of the Suc-LLVY-MCA substrate, in contrast, was markedly re-
duced in liver proteasomes of LCMV-infected mice, as we had
observed consistently in cell lines after IFN- treatment and in cell
lines transfected with LMP2, LMP7, and MECL-1 (7, 8, 10). To-
gether, the results obtained corresponded very well with data obtained
in LMP2/LMP7/MECL-1 triple transfectants (56), indicating that
these marked changes in proteasome activity are probably attributed
to the almost complete replacement of constitutive proteasomes by
immunoproteasomes in the liver of LCMV-infected mice.
Discussion
In this study we analyzed to what extent an exchange of constitu-
tive proteasomes by immunoproteasomes occurs at the steady state
level during viral or bacterial infection of an animal. We found that
the replacement of constitutive proteasomes by immunoprotea-
somes in the liver starts on day 2 of LCMV or Lm infection and
gradually proceeds to an almost complete exchange of protea-
somes in this organ by day 7 or 8 of infection. Simultaneously, the
expression of PA28/ is markedly enhanced, while the PA28
regulator disappears. The extent of 20S proteasome replacement in
the liver is striking and indicates that immunoproteasomes can take
over the numerous housekeeping functions of constitutively ex-
pressed proteasomes at least for a few days. In the priming phase
of the cytotoxic immune response 4 days after LCMV infection,
the proteasome population in the liver consists of about equal
amounts of immunoproteasomes and constitutive proteasomes,
which may enhance the diversity of Ag processing. In the main
effector phase of the CTL response on day 7 or 8 after infection,
however, the balance is shifted toward immunoproteasomes, sug-
gesting that the recognition of infected cells and the clearance of
the pathogen rely on the presentation of epitopes that are produced
by immunoproteasomes under an increased influence of the
PA28/ regulator.
The short time period of 7 days in vivo until the constitutive
proteasomes containing the active site subunits  and MB1 disap-
pear is unexpected, since 20S proteasomes were shown to have an
extraordinarily long half-life of 12–15 days in the liver of meta-
bolically labeled rats (53). Since the replacement of active site
subunits in the proteasome population cannot occur in preformed
and matured 20S proteasomes (55), it relies on the de novo as-
sembly of immunoproteasomes and the relative loss of constitutive
proteasomes. Because of the long half-life of 20S proteasomes, we
expected that immunoproteasomes would at best add a population
to the pre-exisiting constitutive pool until the virus is cleared. A
possible explanation for the rapid elimination of housekeeping
proteasomes in the inflamed liver would be a massive destruction
of LCMV-infected hepatocytes by virus-specific CTLs. Indeed,
serum levels of liver enzymes such as alanine aminotransferase or
aspartate aminotransferase were shown to transiently rise by a fac-
tor of 10–20 in LCMV-WE-infected mice, indicating the lysis of
hepatocytes (47). However, based on the enhancement of alanine
aminotransferase levels, it has been estimated that only 5% of
hepatocytes are lysed during an acute immune response to
LCMV-WE (49) in accordance with the small effect that perforin
deficiency had on proteasome replacements in the liver (Fig. 4). A
histological assessment of LCMV infection by in situ hybridiza-
tion indicated that only 5–10% of hepatocytes contained the viral
mRNA on day 5 after infection, whereas all Kupffer cells were
infected (49). Even if the destroyed tissue would be immediately
replaced by new hepatocytes, a cellular turnover of 10% within 7
days would not suffice to account for a complete proteasome ex-
change if the half-life of constitutive proteasomes in the liver is
12–15 days. It will therefore be interesting to determine the in vivo
half-life of constitutive proteasomes in the liver of LCMV-infected
and uninfected mice to test whether an accelerated degradation of
constitutive 20S proteasomes may occur in inflamed organs. An
alternative contribution to the change in proteasome composition
could be the infiltration of the liver with leukocytes that possess
roughly equal amounts of immunoproteasomes and constitutive
proteasomes in the uninduced state. The total lymphocyte number
in the liver increases by a factor of 100 from day 4 until day 6,
adding up to a total of 20 million lymphocytes/liver throughout
days 6–10 of infection (47). However, even in the peak phase of
the immune response the cell number of lymphocytes is about
10-fold lower than the number of the much larger hepatocytes and
hence contributes only marginally to the total proteasome pool of
the liver.
Our experiments performed in IFN--deficient mice showed
that the induction of PA28/ as well as the disappearance of
PA28 relied entirely on IFN- production in the LCMV-infected
liver. While a vigorous induction of PA28/ by IFN- could be
predicted from previous in vitro data (25), the disappearance of
PA28 after IFN- treatment has not been observed in all cell lines
(M. Groettrup, unpublished observations) and is still a matter of
debate. Our in vivo data clearly support this phenomenon first
observed by Tanahashi et al. (32) and pose the question of its
functional implication. One could imagine that PA28 competes
with PA28/ for binding to the proteasome, which may adversely
affect Ag processing, and we are currently addressing this possi-
bility in our laboratory. Also, the mechanism that leads to the
down-regulation of PA28 protein during LCMV infection needs
to be investigated, because mRNA levels of PA28 are not af-
fected by IFN- treatment of cells in vitro (25). In contrast to the
alteration of PA28 regulators, the replacement of , MB1, and
MC14 by LMP2, LMP7, and MECL-1 did occur in IFN--defi-
cient mice, albeit at a 50% reduced level. Thus, IFN- is required
for a full replacement of constitutive proteasomes by immunopro-
teasomes, but other factors must be able to cause a half-maximal
exchange. TNF- is a prime candidate to mediate this effect, as it
is known to induce LMP2 and LMP7 in vitro (55), and since
TNF- mRNA has been found in the liver 2 days after LCMV-WE
infection (49). The cells that produce IFN- and TNF- during the
first 4 days of infection are most likely NK cells, NKT cells, and
macrophages, respectively. NK cells are found in 4-fold greater
number between days 1–5 of LCMV infection in the liver (57).
However, our real-time RT-PCR analysis revealed that the en-
hancement of TNF- and IFN- mRNAs was not very prominent
in the liver of C57BL/6 mice on day 4 after LCMV-WE infection
(Table II), which could indicate that other cytokines may also con-
tribute to the early induction of immunoproteasomes. Beginning
on day 5 of infection, LCMV-specific CTLs and Th cells can be
found in the liver (data not shown) (47), which are likely to ac-
count for the strongly elevated levels of IFN- and TNF- ob-
served on day 8 of infection.
Another class of cytokines that is immediately induced after
LCMV infection in vivo is IFN-/ (58, 59). LCMV is a ()
strand RNA virus that replicates via dsRNA intermediates known
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to be potent inducers of IFN-/. Nevertheless, we could not ob-
serve an induction of PA28 (data not shown) or LMP2 and LMP7
after productive infection of a fibroblast line, although the induc-
tion of IFN- could be demonstrated by RT-PCR after LCMV-WE
infection in vitro (K. Schwarz, unpublished observations). This
indicates that a cell-autonomous production of IFN-/ does not
effectively induce immunoproteasomes and that other cytokines,
such as IFN- and TNF-, are required. In accordance with this
result, a deficiency of the IFN-R only marginally affected pro-
teasome exchange in mouse liver after LCMV infection (Fig. 4).
What consequences does virtually complete replacement of con-
stitutive proteasomes by immunoproteasomes have on our under-
standing of the immune response to LCMV in particular and of the
functions of LMP2, LMP7, and MECL-1 induction in general?
Although the CTL response against LCMV has not yet been in-
vestigated in mice that are deficient for LMP2 or LMP7, it is al-
ready clear from studies in IFN-R/ mice that the IFN--me-
diated induction of these proteasome components is not required
for elimination of the virus, although virus titers were elevated and
the CTL response reduced when the IFN-R was genetically ab-
lated (35) or when IFN- was neutralized by Abs in vivo (60, 61).
With respect to the generation of LCMV epitopes, we have re-
cently shown that the transfection of fibroblasts with LMP2,
LMP7, and MECL-1 results in a markedly enhanced presentation
of the H-2Ld-restricted nucleoprotein epitope nucleoprotein 118
and that purified immunoproteasomes produced 6-fold more pre-
cursors of this epitope compared with constitutive proteasomes in
vitro (22). Recently, we have investigated the generation of the
H-2Db-restricted glycoprotein epitopes GP33 and GP276 and
found that IFN- treatment of fibroblasts led to a 4-fold enhanced
presentation of the immunodominant GP33 epitope, whereas the
subdominant GP276 was 3-fold down-regulated (K. Schwarz, un-
published observations), and we are currently investigating
whether these changes can be attributed to alterations in protea-
some composition.
If immunoproteasomes are not required for the bulk production
of MHC class I ligands and if some epitopes are dependent on
LMP2, LMP7, and MECL-1, while others, including important
tumor epitopes, are destroyed, why, then, would an inducible ex-
pression of immuoproteasomes occur in sites of viral infection?
The surprising finding of an almost complete replacement of con-
stitutive proteasomes by immunoproteasomes suggests that rather
than increasing the diversity of proteasome populations, immuno-
proteasomes serve to generate different T cell epitopes in inflamed
as opposed to uninflamed tissues, which normally express ex-
tremely low levels of LMP2, LMP7, and MECL-1 (54). We hy-
pothesize that the replacement of proteasomes in inflamed tissues
serves to focus the immune response on T cell epitopes that are
preferentially or exclusively made by immunoproteasomes. This
change in epitope production may also contribute to avoid auto-
immune assaults if different peptide epitopes are processed from
endogenous housekeeping genes in uninflamed sites as opposed to
sites of viral infection. T cells that recognize an immunoprotea-
some or PA28/ - dependent peptide from a household protein in
an inflammatory site may not find the same peptide in uninflamed
tissues and hence would not cause tissue damage in inappropriate
sites.
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